Phacoemulsification and 25 Gauge (25G) Vitrectomy Versus Phacoemulsification Only in Idiopathic Epiretinal Membranes

NCT ID: NCT01771939

Last Updated: 2013-01-18

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2006-10-31

Study Completion Date

2012-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of the study is to evaluate the difference in Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity, oct retinal thickness and microperimetry in 2 groups of 30 eyes each affected by idiopathic epiretinal membranes that underwent phacoemulsification and 25G pars-plana vitrectomy with internal limiting membrane (ILM) peeling (Group 1) versus phacoemulsification only (Group 2), with a follow-up length up to 5 years.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Idiopathic epiretinal membranes represent a common cause of visual loss in elderly population. Vitrectomy with membrane peeling is nowadays considered the gold standard in the management of such pathology, with very good results either at short-time or at long-time follow up. In case of mild visual impairment due to epiretinal membrane and associated cataract, it is reasonable to treat only the lens pathology (with phacoemulsification and intra-ocular lens (IOL) implantation). In case of symptoms or ophthalmoscopic finding worsening it is always possible to submit patients who only underwent cataract surgery to vitrectomy with membrane peeling. There are, by now, no comparative studies between these two different approaches in medical literature.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Epiretinal Membrane

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

idiopathic epiretinal membranes

Patients in first arm, with worse visual condition, treated with 25-G Vitrectomy and phacoemulsification (cataract intervention)

Group Type EXPERIMENTAL

25-G vitrectomy and phacoemulsification

Intervention Type PROCEDURE

25-G vitrectomy with Internal Limiting Membrane peeling and phacoemulsification (cataract intervention)

idiopathic epiretinal membrane

Patient in second arm, with better pre-operative condition, treated with phacoemulsification (cataract intervention) only

Group Type ACTIVE_COMPARATOR

phacoemulsification (cataract surgery)

Intervention Type PROCEDURE

lens extraction after phacoemulsification and intra-ocular artificial lens implantation

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

25-G vitrectomy and phacoemulsification

25-G vitrectomy with Internal Limiting Membrane peeling and phacoemulsification (cataract intervention)

Intervention Type PROCEDURE

phacoemulsification (cataract surgery)

lens extraction after phacoemulsification and intra-ocular artificial lens implantation

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Idiopathic epiretinal membranes symptomatic

Exclusion Criteria

* Absence of ocular symptoms, previous retinal interventions
Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Turin, Italy

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Marco Dal Vecchio

MD

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Marco Dal Vecchio, MD

Role: PRINCIPAL_INVESTIGATOR

Clinica Oculistica dell'Università, Ospedale Oftalmico Turin, Italy 10100

Antonio M. Fea, MD, PhD

Role: STUDY_CHAIR

Clinica Oculistica dell'Università, Ospedale Oftalmico Turin, Italy

Carlo A Lavia, MD

Role: PRINCIPAL_INVESTIGATOR

Clinica Oculistica dell'Università, Ospedale Oftalmico Turin, Italy

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Clinica Oculistica dell'Università, Ospedale Oftalmico

Turin, , Italy

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Italy

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

VTCMER2

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.